Breakthrough crosses centers. TAP does not.

A device that has already cleared FDA’s bar for Breakthrough designation reads, reasonably, like a device that has cleared every subsequent bar built on top of it. TAP is not one of those. It is a separate program, run by a single center, and a badge earned under a statute that covers two centers does not carry a sponsor through a door only one of them opened.

One pilot, one commitment letter

The Total Product Life Cycle Advisory Program (TAP) is a voluntary pilot the Center for Devices and Radiological Health launched in January 2023, one of CDRH’s own commitments under the MDUFA V reauthorization covering fiscal years 2023 through 2027. It offers enrolled sponsors more frequent, more structured interaction with CDRH review staff across a device’s development — not a new legal pathway, and not a faster statutory clock, but earlier and denser conversation layered on top of whichever pathway the device already travels. The soft launch enrolled devices through CDRH’s Office of Cardiovascular Devices; the pilot has expanded since, and CDRH intends to add Safer Technologies Program (STeP) devices starting in FY2026, alongside the Breakthrough population it already serves.

The designation reaches further than the program does

Breakthrough Device designation, created by the 21st Century Cures Act at Section 515B of the FD&C Act, is administered primarily by CDRH — but not exclusively. The Center for Biologics Evaluation and Research grants it too, for device-led combination products under its own jurisdiction. A sponsor whose device-led combination product earns Breakthrough designation from CBER has, in every sense the statute cares about, the same designation a CDRH-regulated device holds.

TAP does not follow the designation across that line. FDA’s own program page states plainly that CBER-regulated devices and combination products are, at this time, outside the pilot’s scope — not because they lack Breakthrough status, but because TAP was built as a CDRH pilot, and a combination product’s review already requires coordinating staff outside CDRH in ways the pilot was not designed to absorb.

A designation that reaches across two centers still lands inside a program built to serve only one of them.

Not in the corpus this pipeline reads

TAP enrollment is not a database anywhere — it is a relationship between a sponsor and CDRH review staff, disclosed only at the sponsor’s own discretion, the same way Breakthrough designation itself stays confidential until a sponsor chooses to announce it. Nothing about a device’s TAP status will ever appear in a 510(k) record, a PMA approval order, or a classification entry, so no structured feed — FDA Radar’s four sources included — can surface it. See what we monitor and how often for the rest of that boundary.

The practice

Reading a competitor’s Breakthrough designation and assuming TAP eligibility follows automatically skips a real, center-shaped gate: confirm the device is CDRH-regulated, not a CBER-administered device-led combination product, before treating TAP as available at all. And even inside CDRH, enrollment is not automatic once Breakthrough is granted — TAP has its own capacity and its own invitation. What a competitor’s TAP status, confirmed or assumed, means for a portfolio’s own strategy is a judgment for a regulatory professional working the file; this describes a program boundary, never a recommendation about any specific submission.